Yves Dutronc
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Hair Growth and Disorders, Autoimmune Bullous Skin Diseases, Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Wound Healing and Treatments
Most-Cited Works
- → Modulation of CD1d-restricted NKT cell responses by using N- acyl variants of α-galactosylceramides(2005)323 cited
- → Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN-γ Production by NK-T Cells(2000)219 cited
- → Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study(2017)185 cited
- → The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis(2020)165 cited
- → Prediction of Survival for Patients With Bullous Pemphigoid(2005)163 cited
- → Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)(2023)133 cited
- → Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study(2021)111 cited
- → Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study(2018)100 cited
- → The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials(2020)96 cited
- → “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata(2020)92 cited